CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the publication of a cover article in the current issue of Nature Reviews Cancer summarizing the recent development of improved preclinical modeling approaches to cancer drug development. Citing the accelerated discovery of new cancer genes emerging from large-scale cancer genomics as well as the extensive number of new compounds emerging from the drug discovery pipeline, the authors note the need for improved models to provide crucial insights. The review highlights a growing collection of innovative non-germline genetically engineered mouse (nGEMM) models, an approach core to AVEO’s proprietary cancer biology platform. The authors, who include Joerg Heyer, Ph.D., director, genetic models, AVEO Pharmaceuticals, believe these next generation models will pave the way for much needed efficient and accurate preclinical therapeutic testing.
